Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:10/3/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Oct. 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide (MBP8298) in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the third of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study that has completed recruitment of approximately 510 patients at 68 clinical sites who will be administered either dirucotide (MBP8298) or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 26, 2015 Regenestem Network ... cells clinic in Buenos Aires, Argentina. The clinic will ... care specialist. Pastrana has assembled a multidisciplinary team of ... in her state-of-the-art Puerto Madero office. , The ... to phase IV clinical studies in cellular therapies, and ...
(Date:5/26/2015)... May 26, 2015 Innovacyn, a ... in the human and animal health industries, announced ... Future Innovators of Agriculture College Scholarship Award. The ... who exhibits a passionate commitment to the agriculture ... This year’s winners, Alexis Pedrow from Anderson County ...
(Date:5/26/2015)... REDWOOD CITY, California and HILDEN, ... -- QIAGEN N.V. (NASDAQ: QGEN ... commercial launch of its QIAGEN Clinical Insight ® ... clinical testing labs to interpret and report on ... first two supported applications for the bioinformatics platform ...
(Date:5/26/2015)... Intrexon Corporation (NYSE: XON ), a leader in ... Senior Vice President and Head of Intrexon,s Health Sector, will ... June 3 rd , at 1:30 p.m. Eastern Time at ... . About Intrexon Corporation Intrexon Corporation ... Better DNA ™ to create biologically-based products that improve ...
Breaking Biology Technology:Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5Intrexon to Present at the Jefferies 2015 Global Healthcare Conference 2
... Systems has reached an agreement with UW-Madison for ... , ,The UW-Madison campus serves 41,500 students, 3,800 faculty ... 180 buildings spread across 933 acres. UW-Madison's network services ... personalized window of their financial records, course schedules, e-mail ...
... of a two part article. Click here to read ... company may have no patents and, generally, little perceived need to ... of entities that consider enforcing patents to be a main or ... have to be concerned with patent matters. , ,One enforcement technique ...
... rustling around the biz about how gaming is going to transform ... Advanced Distributed Learning Co-Lab are doing some really fascinating work ... Gaming is just the tip of an iceberg big enough to ... to the boardroom. , ,This is a great time of ...
Cached Biology Technology:Guarding against patent enforcement 2Guarding against patent enforcement 3Guarding against patent enforcement 4Just in time for Christmas: Retail IT. 2Just in time for Christmas: Retail IT. 3
(Date:5/20/2015)... , May 20, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the addition ... the Global Iris Recognition Market"  report ... , ,This research service analyses trends ... the government and commercial sectors, globally. ...
(Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
(Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... disease, extent of tissue damage depends on the balance between ... liver cells. In a significant minority of people who get ... scars. This can progress to chronic liver disease and cirrhosis ... to clean blood or produce vital hormones and clotting factors. ...
... Potential clues to how autism miswires the brain are ... form of the disorders that affects fewer than 20 ... funded by the National Institutes of Health have grown ... wrong in the brain in Timothy Syndrome. Affected children ...
... held theories about the importance of proteins called B-type lamins ... differentiating into different varieties of cells. New research from a ... expectations, these B-type lamins are not necessary for stem cells ... development. Their work is published November 24 by Science ...
Cached Biology News:Neurons grown from skin cells may hold clues to autism 2Neurons grown from skin cells may hold clues to autism 3Surprise role of nuclear structure protein in development 2
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
Request Info...
Purified anti-human CD182 (CXCR2)...
Biology Products: